{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:46:19Z","timestamp":1793249179059,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":66,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-026-01457-3","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T13:25:20Z","timestamp":1777987520000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Survival outcomes with matched targeted therapy in advanced biliary tract cancer: a large global cohort analysis"],"prefix":"10.1038","volume":"10","author":[{"given":"Binbin","family":"Zheng-Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Shibuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi E.","family":"Kosiorek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluseyi","family":"Abidoye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cody R.","family":"Eslinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Kawamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryne C.","family":"Ramaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadayoshi","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuho","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Pirozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Hoyek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad B.","family":"Sonbol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguyen H.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Babiker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis R.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley N.","family":"Moyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Bando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chigusa","family":"Morizane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhuri","family":"Gottam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitesh J.","family":"Borad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Strickler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanios","family":"Bekaii-Saab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"1457_CR1","unstructured":"Surveillance Research Program National Cancer Institute. SEER*Explorer: An interactive website for SEER cancer statistics [Internet]. 2024 updated: November 5, 2024; accessed:November 20, 2024];Available from:https:\/\/seer.cancer.gov\/statistics-network\/explorer\/."},{"key":"1457_CR2","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nm.4333","volume":"23","author":"A Zehir","year":"2017","unstructured":"Zehir, A. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med. 23, 703\u2013713 (2017).","journal-title":"Nat. Med."},{"key":"1457_CR3","doi-asserted-by":"publisher","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","volume":"24","author":"MA Lowery","year":"2018","unstructured":"Lowery, M. A. et al. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention. Clin. Cancer Res. 24, 4154\u20134161 (2018).","journal-title":"Clin. Cancer Res."},{"key":"1457_CR4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jhep.2022.09.004","volume":"78","author":"JJ Harding","year":"2023","unstructured":"Harding, J. J. et al. Rational development of combination therapies for biliary tract cancers. J. Hepatol. 78, 217\u2013228 (2023).","journal-title":"J. Hepatol."},{"key":"1457_CR5","unstructured":"FDA. FDA approves pembrolizumab for adults and children with TMB-H solid tumors. June 17, 2020 November 20, 2024]; Available from:https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors."},{"key":"1457_CR6","unstructured":"FDA. FDA grants accelerated approval to pembrolizumab for first tissue\/site agnostic indication. May 30, 2017 November 19, 2024]; Available from:https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication."},{"key":"1457_CR7","unstructured":"National Comprehensive Cancer Network. Biliary Tract Cancers (Version 4.2024). November 12, 2024]; Available from:https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/btc.pdf."},{"key":"1457_CR8","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1016\/S1470-2045(19)30733-8","volume":"21","author":"SH Tella","year":"2020","unstructured":"Tella, S. H. et al. Second-line therapies in advanced biliary tract cancers. Lancet Oncol. 21, e29\u2013e41 (2020).","journal-title":"Lancet Oncol."},{"key":"1457_CR9","doi-asserted-by":"crossref","unstructured":"Garajova, I., et al., Second-line chemotherapy for intrahepatic cholangiocarcinomas: What is the real gain? Life, 13 (2023).","DOI":"10.3390\/life13112170"},{"key":"1457_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-42083-4","volume":"13","author":"B Doleschal","year":"2023","unstructured":"Doleschal, B. et al. Real world evidence reveals improved survival outcomes in biliary tract cancer through molecular matched targeted treatment. Sci. Rep. 13, 15421 (2023).","journal-title":"Sci. Rep."},{"key":"1457_CR11","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1158\/1078-0432.CCR-21-2384","volume":"28","author":"H Verdaguer","year":"2022","unstructured":"Verdaguer, H. et al. ESMO scale for clinical actionability of molecular targets driving targeted treatment in patients with cholangiocarcinoma. Clin. Cancer Res. 28, 1662\u20131671 (2022).","journal-title":"Clin. Cancer Res."},{"key":"1457_CR12","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/ijc.33230","volume":"148","author":"R Okamura","year":"2021","unstructured":"Okamura, R. et al. Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers. Int. J. Cancer 148, 702\u2013712 (2021).","journal-title":"Int. J. Cancer"},{"key":"1457_CR13","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","volume":"29","author":"J Mateo","year":"2018","unstructured":"Mateo, J. et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann. Oncol. 29, 1895\u20131902 (2018).","journal-title":"Ann. Oncol."},{"key":"1457_CR14","doi-asserted-by":"publisher","first-page":"103647","DOI":"10.1016\/j.esmoop.2024.103647","volume":"9","author":"LT Chen","year":"2024","unstructured":"Chen, L. T. et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer. ESMO Open 9, 103647 (2024).","journal-title":"ESMO Open"},{"key":"1457_CR15","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.jhep.2024.10.020","volume":"82","author":"S Hwang","year":"2025","unstructured":"Hwang, S. et al. Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer. J. Hepatol. 82, 649\u2013657 (2025).","journal-title":"J. Hepatol."},{"key":"1457_CR16","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.annonc.2022.09.150","volume":"33","author":"JE Berchuck","year":"2022","unstructured":"Berchuck, J. E. et al. The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer. Ann. Oncol. 33, 1269\u20131283 (2022).","journal-title":"Ann. Oncol."},{"key":"1457_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-49860-0","volume":"9","author":"TJ Ettrich","year":"2019","unstructured":"Ettrich, T. J. et al. Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information. Sci. Rep. 9, 13261 (2019).","journal-title":"Sci. Rep."},{"key":"1457_CR18","doi-asserted-by":"publisher","first-page":"104003","DOI":"10.1016\/j.esmoop.2024.104003","volume":"10","author":"A Vogel","year":"2025","unstructured":"Vogel, A. & Ducreux, M. and E.G.C.E.a. clinicalguidelines@esmo.org, ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer. ESMO Open 10, 104003 (2025).","journal-title":"ESMO Open"},{"key":"1457_CR19","unstructured":"FDA. FDA grants accelerated approval to pemigatinib for cholangiocarcinoma with an FGFR2 rearrangement or fusion. April 20, 2020 November 20, 2024]; Available from:https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pemigatinib-cholangiocarcinoma-fgfr2-rearrangement-or-fusion."},{"key":"1457_CR20","unstructured":"FDA. FDA grants accelerated approval to futibatinib for cholangiocarcinoma. September 30, 2022 November 20, 2024]; Available from:https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-futibatinib-cholangiocarcinoma."},{"key":"1457_CR21","unstructured":"FDA. FDA approves ivosidenib for advanced or metastatic cholangiocarcinoma. February 1, 2022 November 20, 2024]; Available from:https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ivosidenib-advanced-or-metastatic-cholangiocarcinoma."},{"key":"1457_CR22","doi-asserted-by":"crossref","unstructured":"Pappas, L. et al., The Cholangiocarcinoma in the Young (CITY) Study: tumor biology, treatment patterns, and survival outcomes in adolescent young adults with cholangiocarcinoma. JCO Precis. Oncol., e2200594 (2023).","DOI":"10.1200\/PO.22.00594"},{"key":"1457_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104540","volume":"10","author":"D Malka","year":"2025","unstructured":"Malka, D. et al. Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomised, controlled, open-label, phase III umbrella trial (SAFIR-ABC10-Precision Medicine). ESMO Open 10, 104540 (2025).","journal-title":"ESMO Open"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01457-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01457-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01457-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:46:17Z","timestamp":1783637177000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01457-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1457"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01457-3","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]},"assertion":[{"value":"11 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Mohamad SonbolHonoraria\u2014NovartisResearch Funding\u2014Lilly (Inst); Taiho Oncology (Inst) Christina WuHonoraria\u2014Cancer Treament Centers of America; MedscapeConsulting or Advisory Role\u2014Daiichi Sankyo\/Lilly; Exelixis; Natera; Natera; Nova Research Company; Pfizer; SeagenResearch Funding\u2014HUTCHMED; Pfizer; Sirnaomics (Inst); Sumitomo Pharma (Inst) Nguyen TranHonoraria\u2014Helsinn Therapeutics (Inst); QED Therapeutics (Inst)Consulting or Advisory Role\u2014AstraZeneca (Inst); QED Therapeutics (Inst); TEMPUS (Inst)Research Funding\u2014Exact Sciences Hani BabikerConsulting or Advisory Role\u2014Celgene; Endocyte; Idera; Myovant Sciences; NovocureSpeakers\u2019 Bureau\u2014Guardant Health Takayuki YoshinoHonoraria\u2014Chugai Pharma; Merck; MSD K.K.; TakedaConsulting or Advisory Role\u2014Sumitomo Corp.Research Funding\u2014Amgen (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Eisai (Inst); FALCO biosystems Ltd. (Inst); Medical & Biological Laboratories Co., Ltd. (Inst); Merus (Inst); Molecular Health (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst) Masafumi IkedaHonoraria\u2014Abbvie; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; EA Pharma; Eisai; Fujifilm; Guardant Health; Incyte; Lilly Japan; MSD; Nihonkayaku; Nobelpharma; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Taisho Pharmaceutical Holdings; Takeda; Teijin Pharma; Yakult PharmaceuticalConsulting or Advisory Role\u2014Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Boston Scientific; Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; Guardant Health; MSD; Novartis; Roche; SERVIERResearch Funding\u2014AstraZeneca (Inst); Bayer Yakuhin (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); InVitae (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); Merus NV (Inst); MSD (Inst); Nihon Servier (Inst); Nobelpharma (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Rakuten Medical Japan (Inst); Syneos Health (Inst) Chigusa MorizaneHonoraria\u2014AstraZeneca; Chugai Pharma; Eisai; Guardant Health; Incyte Japan; MSD K.K.; Myriad Genetics; Novartis; Taiho Pharmaceutical; Yakult HonshaConsulting or Advisory Role\u2014AstraZeneca; Boehringer Ingelheim; Merck; MSD K.K.; SERVIER; Taiho Pharmaceutical; Yakult HonshaResearch Funding\u2014AstraZeneca (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo RD Novare; Eisai (Inst); EPS Corporation (Inst); Hitachi (Inst); J-Pharma (Inst); LabCorp (Inst); Merck (Inst); ONO PHARMACEUTICAL (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst) Hideaki BandoHonoraria\u2014Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical Yoshiaki NakamuraConsulting or Advisory Role\u2014DAIICHI SANKYO Co., Ltd.; Exact Sciences; Gilead Sciences; Guardant Health Pte Ltd; Natera,Inc.; Premo Partners, Inc.; Roche Ltd.\/; Seagen,Inc.; TakedaSpeakers\u2019 Bureau\u2014Becton Dickinson; CareNet,Inc.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Guardant Health Japan Corp.; Guardant Health Pte Ltd; Hisamitsu Pharmaceutical; Merck; Miyarisan pharmaceutical; MSD K.K; Taiho Pharmaceutical; Zeria PharmaceuticalResearch Funding\u2014Chugai Pharma (Inst); DAIICHI SANKYO Co., Ltd. (Inst); Genomedia (Inst); Guardant Health (Inst); Guardant Health AMEA, Inc. (Inst); Roche (Inst); Seagen,Inc. (Inst); Tempus (Inst) Takao FujisawaHonoraria\u2014Amelief; Merck Serono Daniel AhnStock and Other Ownership Interests\u2014NateraConsulting or Advisory Role\u2014Advanced Accelerator Applications; Daiichi Sankyo\/Astra Zeneca; Eisai; Exelixis; Genentech\/Roche; Incyte; Incyte; NovartisResearch Funding\u2014AstraZeneca; Bayer Mitesh BoradConsulting or Advisory Role\u2014BJ Bioscience; Genentech; Imvax; Kriya Therapeutics; Lynx Group; Merck; Senti Biosciences; Tempus; ZymeworksResearch Funding\u2014Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Basilea (Inst); Biond Biologics (Inst); Celgene (Inst); Eisai (Inst); EMD Serono (Inst); Halozyme (Inst); Incyte (Inst); Incyte (Inst); Isis Pharmaceuticals (Inst); Kinnate Biopharma (Inst); MedImmune (Inst); Merck Serono (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Qurient (Inst); RedHill Biopharma (Inst); Relay Therapeutics (Inst); Senhwa Biosciences (Inst); Sillajen (Inst); Taiho Pharmaceutical (Inst); ZielBio (Inst) Tanios Bekaii-SaabConsulting or Advisory Role\u2014Abbvie; Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca; Bayer (Inst); BeiGene; Boehringer Ingelheim; Caladrius Biosciences; Caladrius Biosciences; Celularity; Daiichi Sankyo\/UCB Japan; Deciphera; Eisai; Eisai; Exact Sciences; Foundation Medicine; Foundation Medicine; Illumina; Immuneering; Incyte (Inst); Ipsen (Inst); Janssen; Kanaph Therapeutics; Lilly (Inst); Natera; Pfizer (Inst); Roche\/Genentech (Inst); Seagen (Inst); SOBI; Stemline Therapeutics; Treos Bio; Zai LabPatents, Royalties, Other Intellectual Property\u2014Patent WO\/2018\/183488; Patent WO\/2019\/055687.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"268"}}